Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain

References

• Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284:311–8.
   PubMed Web of Science ®Google Scholar
• Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:56–64.
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 2002;324:1570–6.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115: e356–75.
   PubMedGoogle Scholar
• ; The Emerging Risk Factors CollaborationErqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA. 2009;302:412–23.
   PubMed Web of Science ®Google Scholar
• ; The Lp-PLA2 Studies CollaborationThompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375: 1536–44.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112:651–7.
   PubMed Web of Science ®Google Scholar
• Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the Rosuvastatin-JUPITER controversy. Arch Intern Med. 2010;170:1032–6.
   Google Scholar
• Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879–91.
   PubMed Web of Science ®Google Scholar
• Shao B, Oda MN, Oram JF, Heinece JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high-density lipoprotein. Curr Opin Cardiol. 2006;21:322–8.
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Stores ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50;159–65.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest. 2008;38:90–6.
   PubMed Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predicts risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–5.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–604.
   PubMed Web of Science ®Google Scholar
• Lobbes MI, Kooi ME, Lutgens E, Ruiters AW, Lima Passos V, Braat SH, et al. Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein A as biomarkers for cardiovascular disease: towards a multi-biomarker approach. Int J Vasc Med. 2010;43:240–5.
   Google Scholar
• Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011;32:697–705.
   PubMed Web of Science ®Google Scholar
• Schaub N, Reichlin T, Meune C, Twerenbold R, Haaf P, Hochholzer W, et al. Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem. 2012;58:246–56.
   PubMed Web of Science ®Google Scholar
• Vaara S, Nieminen MS, Lokki ML, Perola M, Pussinen PJ, Allonen J, et al. Cohort profile: the Corogene study. Int J Epidemiol. 2012;41: 1265–71.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
   PubMed Web of Science ®Google Scholar
• Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55:2737–42.
   Google Scholar
• Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871–8.
   PubMed Web of Science ®Google Scholar
• Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem. 2008;54:1076–9.
   PubMed Web of Science ®Google Scholar
• Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis. 2010;210:194–8.
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Trip MD, van Wissen S, van Miert JN, Kastelein JJ, Stroes ES. Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis. 2008;197:916–21.
   Google Scholar
• Stenvinkel P, Rodriques-Ayala E, Massy ZA, Quereshi AR, Barany B, Fellström B, et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:281–7.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta. 2006;368:168–72.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Schömig A, Kastrati A. Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol. 2011;100:327–33.
   Google Scholar
• Lima LM, Carvalho MG, Neto CP, Garcia JC, Sousa MO. Secretory phospholipase A2 in patients with coronary artery disease. J Thromb Thrombolysis. 2010;29:276–81.
   Google Scholar
• Mallat Z, Steg G, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249–57.
   PubMed Web of Science ®Google Scholar